Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DNIB0600A: Additional Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 38 evaluable NSCLC or platinum-resistant ovarian cancer patients with immunohistochemistry (IHC) scores of 2/3+ for tumor NaPi2b

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE